Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Claritin Supply Sufficient For Spring, Schering Says; FDA Lists GMP Problems

Executive Summary

Schering-Plough will have a sufficient supply of Claritin for the spring allergy season, the company maintains.

You may also be interested in...



Schering Albuterol Recall Linked With 24 Fatalities, Public Citizen Asserts

Schering-Plough's testing of albuterol inhalers returned to the company shows that in every case where an injury is alleged to have occurred because of a faulty inhaler, the canister contained active ingredient, the company maintains.

Schering Albuterol Recall Linked With 24 Fatalities, Public Citizen Asserts

Schering-Plough's testing of albuterol inhalers returned to the company shows that in every case where an injury is alleged to have occurred because of a faulty inhaler, the canister contained active ingredient, the company maintains.

Nasonex Delivery Failures Are Among Observations In Schering FDA-483s

One theme of FDA's recent inspections of Schering-Plough's Manati, Puerto Rico manufacturing facility is the reliability of the nasal spray delivery system for Nasonex (mometasone).

Related Content

UsernamePublicRestriction

Register

PS037419

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel